Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CIGB-814 in Healthy Participants
NCT07182656Phase 1Recruiting
- Sponsor
- InventisBio
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CIGB-814 in rheumatoid arthritis (RA) (4 arms), sponsored by InventisBio. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Plasma Concentration and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
CIGB-814
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07182656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182656.